Premium
Development of an enzyme‐linked immunosorbent assay (ELISA) for detecting IgA antibodies to the epstein‐barr virus
Author(s) -
Uen WuChing,
Luka Janos,
Pearson Gary R.
Publication year - 1988
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910410402
Subject(s) - antibody , glycoprotein , monoclonal antibody , antigen , nasopharyngeal carcinoma , virus , epstein–barr virus , virology , biology , microbiology and biotechnology , immunoglobulin a , immunology , immunoglobulin g , medicine , radiation therapy
A 3‐step enzyme‐linked immunosorbent assay (ELISA) was developed for detecting IgA antibodies Co purified Epstein‐Barr virus (EBV) polypeptides. The 3‐step procedure included the use of a mouse anti‐human IgA monoclonal antibody (MAb) to amplify the IgA reaction. The 2 major EBV proteins used in this assay were the 125‐kDa component (gpl25) associated with the viral capsid antigen (VCA) complex and a major glycoprotein (gp 250/200) associated with the membrane antigen (MA) complex. Eighty‐two sera were tested on ELISA plates containing either both of the glycoproteins or each one separately. These included 45 IgA antibody‐positive sera from patients with nasopharyngeal carcinoma {NPC). With these sera, there was a good correlation, both qualitatively and quantitatively, between results with the immuno‐fluorescence (IF) and ELISA procedures. Although most IgA antibody‐positive sera contained antibodies reactive with both gpl2S and gp250/200, a number of sera contained antibodies reactive with one of the glycoproteins but not with both. The data indicated that both of these glycoproteins should be used in assays for detecting IgA antibodies to EBV, to avoid false‐negative results. This assay should be useful for screening large populations for IgA antibodies to EBV and also possibly for monitoring disease course in patients with NPC.